← Back

EMA - European Medicines Agency · EU-wide · 18 Nov 2026 · Administrative

Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting

AI-generated summary

The EMA's Quality Innovation Group is holding a roundtable meeting on November 18, 2026, in Amsterdam to discuss digitalisation and artificial intelligence in pharmaceutical manufacturing. The meeting will bring together industry, academia, and regulators to exchange knowledge on developing and implementing digital and AI technologies, explore regulatory challenges, and support collaboration on future perspectives. Participants are invited to present case studies demonstrating how these technologies apply to manufacturing and quality control.

From EMA - European Medicines Agency

- Wednesday, November 18, 2026 - 09:00 - 17:30 Amsterdam time (CET)

Digitalisation and artificial intelligence (AI) are transforming pharmaceutical development and manufacturing at an unprecedented pace.

Advances in data analytics, automation, machine learning, digital twins, and other AI-enabled technologies are creating new opportunities. These include enhancing product quality, manufacturing efficiency, supply chain resilience. These changes can also improve decision-making across the pharmaceutical product lifecycle.

EMA's Quality Innovation Group (QIG) is organising a roundtable meeting with representatives from industry, academia and regulators to support dialogue on these rapid developments. Broad topics for discussion include:

- Latest scientific and technological advances

- Current progress in the application of digitalisation and AI in pharmaceutical manufacturing

Meeting objectives

The meeting aims to provide a forum for the exchange of knowledge and practical experience on the development, implementation, and use of digital and AI-enabled technologies in the fields mentioned.

It also aims to explore scientific and regulatory challenges associated with these technologies and consider potential approaches to address them.

In addition, it looks to support continued collaboration on the opportunities, challenges, and future perspectives associated with digitalisation and AI in pharmaceutical manufacturing.

Moreover, meeting discussions are meant to help QIG gain insight into emerging scientific and technological developments. This enables the timely provision of regulatory support as well as fostering a shared understanding of innovation in AI.

Participants

The meeting is intended for stakeholders in industry and academia involved in the development, implementation, application, or regulation of digital and AI-enabled technologies in the mentioned fields.

Participants are invited to present recent related case studies that illustrate how digitalisation and AI applies in manufacturing and quality control.

Previous meetings

The meeting builds on previous QIG listen-and-learn focus group (LLFG) meetings from 2023 and 2024 focused on digitalisation and pharmaceutical process models in manufacturing. The experience gained through numerous one-on-one QIG meetings with stakeholders also contributed towards this meeting.

For more information, see:

Live broadcast

Day 1 - -

Day 2 - -

Video quality

To view the video in the highest quality, click Settings in the bottom right-hand corner of the video and select High.

To watch the video in full screen mode, click the arrow icon to watch it on Panopto.

Excerpt from the official page. The original is authoritative.